Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of SARS-CoV-1 3CL protease expressed in Escherichia coli using HiyteFluor-488ESATLQSGLRKAK-(QXL)-NH2 as substrate incubated for 30 min by FRET assay
Assay data:30 Active, 20 Activity ≤ 1 µM, 37 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed Citation
Antiviral activity against SARS Cov-2 USA_WA1/2020 infected in Vero E6 cells expressing ACE2 reporter assessed as inhibition of viral cytopathic effect measured after 68 hrs post infection by neutral red uptake assay
Assay data:11 Active, 2 Activity ≤ 1 µM, 13 Tested
Antiviral activity against SARS Cov-2 USA_WA1/2020 infected in Vero E6 cells expressing ACE2 reporter assessed as reduction in plaque formation at 0.21 to 50 uM and measured at 3 days post-infection by crystal violet staining based assay
Assay data:9 Active, 2 Activity ≤ 1 µM, 13 Tested
Inhibition of SARS-CoV-2 3CL protease expressed in Escherichia coli using HiyteFluor-488ESATLQSGLRKAK-(QXL)-NH2 as substrate incubated for 30 min by FRET assay
Assay data:32 Active, 18 Activity ≤ 1 µM, 38 Tested
plaque reduction assay from Article 10.1021/acs.jmedchem.1c00598: "Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL"
Assay data:8 Active, 1 Activity ≤ 1 µM, 12 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
CPE inhibition assay from Article 10.1021/acs.jmedchem.1c00598: "Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL"
Assay data:10 Active, 1 Activity ≤ 1 µM, 12 Tested
SARS-CoV-1 and -2 3CLpro Biochemical Assay from Article 10.1021/acs.jmedchem.1c00598: "Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL"
Assay data:32 Active, 21 Activity ≤ 1 µM, 37 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on